From the 2021 online meeting of the European Society for Clinical Virology, Vincent speaks with meeting speakers on COVID-19 vaccines, immunity, how countries responded to the pandemic, and how to prepare for the next one.
TWiV considers lessons learned from COVID-19 about emergency drug use during a pandemic, and selection of AAV capsids to produce vectors that efficiently deliver genes to muscle cells.
In COVID-19 clinical update #82, Daniel Griffin reviews vaccines for 5-12 years old, safety of a third vaccine dose, Oklahoma reinfection data, Regencov outcomes, Pfizer protease inhibitor, impact of Tocilizumab, and incidence of long COVID.
TWiV reviews how a novel technology enabled development of COVID-19 mRNA vaccines, and discovery of a proton gradient and an incomplete TCA cycle in a giant. virus.
TWiV reveals isolation from bats in Laos of a SARS-CoV-2 like virus with a spike protein that allows entry into human cells, and exploration of a herpesvirus vector for immunization of vampire bats against rabies virus.
In COVID-19 clinical update #81, Daniel Griffin discusses vaccine boosters, vaccination during pregnancy, mRNA vaccine comparison, J&J vaccine booster, EUA expansion for Lilly monoclonals, remdesivir reduces risk of hospitalization, and anticoagulation regimens.
Chadi and Caroline join TWiV to describe the potential epidemiological and evolutionary impacts of vaccine nationalism, and their modeling which emphasizes the importance of rapid equitable vaccine distribution for global control of the pandemic.
In COVID-19 clinical update #80, Daniel Griffin reviews infections in children, masking, testing to limit transmission, high barrier for monoclonal antibody escape, are boosters needed, use of steroids, grants for long COVID, and how the pandemic unfolds in Africa.
Virus hunter Mya Breitbart joins TWiV to describe her laboratory’s work on viruses in spiders, insects, millipedes, freshwater springs, seawater, plants, human feces and much more.
In COVID-19 clinical update #79, Daniel Griffin discusses clinical management guidelines, ER visits and hospitalization among children, infection and vaccine induced seroprevalence in the US, antibodies in Kenyan blood donors, infections after vaccination, anticoagulation for thromboprophylaxis, baracitinib efficacy, long-term symptoms in adults, and sustained symptoms after severe disease.